Skip to content
Menu

NeOnc Technologies Holdings Says FDA Reschedules End-Of-Phase 1 Meeting For Oral NEO212 To November 23

Benzinga Newsdesk 1 day ago

NewsFDA

Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the

Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212

CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has rescheduled the Company’s End-of-Phase 1 Type B meeting concerning oral NEO212 from the previously announced date of November 17, 2026, to Monday, November 23, 2026.

At the meeting, NeOnc intends to seek FDA feedback on its NEO212 clinical development program, including the proposed patient population, trial design, endpoints and dose selection for the Phase 2 portions of the NEO212-01 trial, as well as potential regulatory pathways for NEO212. The meeting provides an opportunity for discussion; its scheduling does not establish FDA agreement on a trial design or eventual approval of NEO212.

The meeting follows completion of the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. NeOnc previously reported that dose escalation was discontinued following a dose-limiting toxicity at 810 mg, administered once daily on Days 1 through 5 of a 28-day cycle, and that 610 mg was selected as the recommended Phase 2 dose. In September 2025, FDA authorized the Company to proceed with the Phase 2a and Phase 2b portions of NEO212-01.

NeOnc has also reported encouraging clinical activity observed during the Phase 1 portion of the trial. In one patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma (GBM), treatment with NEO212 resulted in a partial response, including an approximately 60% reduction in tumor size, followed by prolonged disease control lasting 21 treatment months. In a second patient with lung cancer metastatic to the brain who had previously received and progressed following multiple lines of therapy, including immune checkpoint inhibitors, treatment with NEO212 was associated with stable disease lasting approximately 16 months. While these individual patient outcomes do not establish efficacy and require confirmation in larger studies, they provide the clinical rationale for further evaluation of NEO212 in the Phase 2 portions of the NEO212-01 trial.

Read at benzinga.com

← All stock news